---
layout: default
title: Liraglutide
parent: 僅模型預測 (L5)
nav_order: 209
evidence_level: L5
indication_count: 0
---

# Liraglutide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Liraglutide: From Type 2 Diabetes / Obesity — Repurposing Target TBD

---

## One-Sentence Summary

Liraglutide is a GLP-1 receptor agonist, approved in multiple markets for the management of Type 2 Diabetes mellitus and chronic weight management.
This Evidence Pack currently contains **no TxGNN repurposing predictions**, as two critical data gaps — missing mechanism of action (MOA) data and absent safety/contraindication records — are blocking the prediction pipeline from completing.
With **0 predicted indications** generated, a full repurposing evaluation **cannot proceed** until these gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Type 2 Diabetes / Chronic Weight Management *(based on known drug profile; not populated in this Evidence Pack)* |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Prediction pending; no supporting studies retrievable at this stage |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | **Hold** |

---

## Why Are Predictions Pending?

Liraglutide (DrugBank ID: DB06655) is a well-established glucagon-like peptide-1 (GLP-1) receptor agonist. In clinical practice it is marketed as **Victoza** (Type 2 Diabetes) and **Saxenda** (chronic weight management), and has demonstrated cardiovascular risk reduction benefits in landmark trials such as LEADER. GLP-1 receptor agonists generally work by stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and inducing satiety — a multi-target profile that has attracted considerable interest for repurposing into metabolic liver disease (MASH/NAFLD), neurodegenerative conditions, and polycystic ovary syndrome (PCOS), among others.

However, **the TxGNN model has not generated any repurposing candidates** for this drug in the current Evidence Pack. Two identified data gaps are directly responsible:

1. **DG002 — Mechanism of Action (High severity):** The MOA field is unpopulated. The TxGNN knowledge graph relies on confirmed target-pathway annotations to compute cross-indication similarity scores. Without this anchor, mechanistic-linkage analysis cannot be executed.

2. **DG001 — Safety Warnings & Contraindications (Blocking severity):** Package insert data has not been retrieved. The S1 safety pre-screening gate — which checks for known absolute contraindications before a repurposing candidate advances — cannot be cleared without this information.

Until both gaps are remediated and the pipeline is re-run, no repurposing direction can be formally scored or ranked.

---

## Malaysia Market Information

The Evidence Pack confirms **4 active product registrations** with Malaysia's NPRA, but detailed license records (authorization numbers, product names, dosage forms, and approved indication text) were not retrieved in this Evidence Pack version.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| — | — | — | *(Details not retrieved — NPRA registry query required)* |
| — | — | — | *(Details not retrieved — NPRA registry query required)* |
| — | — | — | *(Details not retrieved — NPRA registry query required)* |
| — | — | — | *(Details not retrieved — NPRA registry query required)* |

> **Note:** 4 registrations are confirmed as active. Full license details must be pulled from the NPRA portal to complete this table before the Malaysia section can contribute to the evaluation.

---

## Safety Considerations

All safety fields in this Evidence Pack carry a data gap status:

- **Key Warnings:** Not retrieved — package insert PDF from the official source must be parsed *(Blocking: DG001)*
- **Contraindications:** Not retrieved — same remediation as above *(Blocking: DG001)*
- **Drug-Drug Interactions:** Query returned no results (0 interactions identified in current data sources)

> Please refer to the approved package insert for complete safety information. The absence of warnings and contraindication data is a **Blocking** issue that prevents the mandatory S1 safety pre-screening step from being completed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is critically incomplete — no TxGNN repurposing predictions have been generated, all safety data is absent at Blocking severity, and product license details were not retrieved. There is no evaluable candidate indication at this time, and advancing any repurposing hypothesis without a cleared safety screen would be premature.

**To proceed, the following is needed:**

1. **Resolve DG001 (Blocking) — Retrieve package insert:**
   Download the NPRA-approved package insert PDF for all 4 registered liraglutide products and extract key warnings, contraindications, and special population precautions.

2. **Resolve DG002 (High) — Populate MOA:**
   Query the DrugBank API for DB06655 to retrieve confirmed pharmacological targets, mechanism description, and pathway annotations. This data is essential for TxGNN's mechanistic graph traversal.

3. **Re-run TxGNN prediction pipeline:**
   Once MOA and safety data are populated, re-execute both the knowledge-graph (KG) and deep-learning (DL) prediction models to generate a ranked `predicted_indications` list.

4. **Retrieve full NPRA license details:**
   Query the NPRA registry for all 4 registrations to populate authorization numbers, product names, dosage forms, and approved indication texts.

5. **Re-generate and re-submit the Evidence Pack:**
   After the above steps, regenerate the Evidence Pack (targeting version v5) and resubmit for a full repurposing evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

